title: [Gene expression profile of medullary thyroid carcinoma--preliminary results].
abstract: BACKGROUND
  Medullary thyroid carcinoma occurs both as a sporadic and a familial disease. Inherited MTC (iMTC) patients usually exhibit better prognosis than patients with sporadic form of MTC (sMTC), however, in both subtypes the outcome is unpredictable. No molecular markers contributing to the prognosis or predicting the type of therapy have been introduced to clinical practice until now. The aim of this study was to analyze gene expression pattern of MTC by high density oligonucleotide microarray.
  
  
  METHODS
  24 samples were studied: 12 MTC and 12 corresponding normal tissues, (Affymetrix HG-U 133A). Among MTC patients there were half inherited cases and half sporadic ones.
  
  
  RESULTS
  First, the differences between MTC and thyroid tissue were analyzed by Singular Value Decomposition (SVD) which indicated three main modes determining the variability of gene expression profile: the first two were related to the tumor/normal tissue difference and the third one was related to the immune response. The characteristic expression pattern, beside of numerous changes within cancer- related genes, included many up-regulated genes specific for thyroid C cells. Further analysis of the second component revealed two subgroups of MTC, but the subdivision was not related to the iMTC/sMTC difference. Recursive Feature Replacement (RFR) confirmed the very similar expression profile in both forms of MTC. With subsequent ANOVA analysis some genes with differential expression could be specified, among them monoamine oxidase B (MAOB) and gamma-aminobutyric acid receptor (GABRR1) which were consistently up-regulated in sMTC. In contrary, some genes involved in regulation of cell proliferation: opioid growth factor receptor(OGFR) and synaptotagmin V (SYT 5) were up-regulated in iMTC.
  
  
  CONCLUSIONS
  The obtained data indicate a very similar gene expression pattern in inherited and sporadic MTC. Minor differences in their molecular profile require further analysis.
authors.affiliation: Department of Nuclear Medicine and Endocrine Oncology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice Branch.
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Oczko-Wojciechowska
authors.forename: Jan
authors.initials: J
authors.lastname: Włoch
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Wiench
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Fujarewicz
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Simek
authors.forename: Grzegorz
authors.initials: G
authors.lastname: Gala
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Gubała
authors.forename: Sylwia
authors.initials: S
authors.lastname: Szpak-Ulczok
authors.forename: Barbara
authors.initials: B
authors.lastname: Jarzab
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics*; D018276:Carcinoma, Medullary / Q000175:diagnosis* / Q000235:genetics*; D020869:Gene Expression Profiling; D006801:Humans; D018813:Multiple Endocrine Neoplasia Type 2a / Q000175:diagnosis / Q000235:genetics; D018814:Multiple Endocrine Neoplasia Type 2b / Q000175:diagnosis / Q000235:genetics; D017354:Point Mutation; D011110:Polymorphism, Genetic; D011518:Proto-Oncogene Proteins / Q000235:genetics; D051096:Proto-Oncogene Proteins c-ret; D013964:Thyroid Neoplasms / Q000175:diagnosis* / Q000235:genetics*
chemical_list: D014408:Biomarkers, Tumor; D011518:Proto-Oncogene Proteins; D051096:Proto-Oncogene Proteins c-ret